Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Wood

Showing results (11-20 of 341) with videos related to

Pageof 35
Sort By:
Cancer|July 29, 2008
Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer?Vitaly Margulis, Christopher G Wood
European Urology|January 22, 2008
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?Vitaly Margulis, Christopher G Wood
The Journal of Urology|May 25, 2013
Cytoreductive nephrectomy for metastatic renal cell carcinomaJames McKiernan, Christopher G Wood
BJU International|November 15, 2008
Pre-surgical targeted molecular therapy in renal cell carcinomaVitaly Margulis, Christopher G Wood
Future Oncology (London, England)|August 12, 2009
Vitespen: a preclinical and clinical reviewChristopher G Wood, Peter Mulders
Hematology/Oncology Clinics of North America|July 19, 2011
The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomyJose A Karam, Christopher G Wood
Nature Reviews. Urology|June 17, 2009
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapyE Jason Abel, Christopher G Wood
European Urology|April 26, 2011
The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant?Brian F Chapin, Christopher G Wood
European Urology|February 8, 2012
Management of small renal masses: watch, cut, freeze, or fry?Jose A Karam, Christopher G Wood
Current Opinion in Urology|July 3, 2009
The role of lymphadenectomy in renal cell carcinomaScott E Delacroix, Christopher G Wood
Pageof 35

Showing results (11-20 of 341) with videos related to

Sort By:
Pageof 35
Cancer|July 29, 2008
Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer?Vitaly Margulis, Christopher G Wood
European Urology|January 22, 2008
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?Vitaly Margulis, Christopher G Wood
The Journal of Urology|May 25, 2013
Cytoreductive nephrectomy for metastatic renal cell carcinomaJames McKiernan, Christopher G Wood
BJU International|November 15, 2008
Pre-surgical targeted molecular therapy in renal cell carcinomaVitaly Margulis, Christopher G Wood
Future Oncology (London, England)|August 12, 2009
Vitespen: a preclinical and clinical reviewChristopher G Wood, Peter Mulders
Hematology/Oncology Clinics of North America|July 19, 2011
The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomyJose A Karam, Christopher G Wood
Nature Reviews. Urology|June 17, 2009
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapyE Jason Abel, Christopher G Wood
European Urology|April 26, 2011
The RENAL nephrometry nomogram: statistically significant, but is it clinically relevant?Brian F Chapin, Christopher G Wood
European Urology|February 8, 2012
Management of small renal masses: watch, cut, freeze, or fry?Jose A Karam, Christopher G Wood
Current Opinion in Urology|July 3, 2009
The role of lymphadenectomy in renal cell carcinomaScott E Delacroix, Christopher G Wood
Pageof 35